1143578-94-2

1143578-94-2 structure

Name: TAK 21d
Chemical Name: 4-[4-(3,4-Difluorophenyl)-2-pyrimidinyl]-N-(3-pyridazinyl)-1-piperazinecarboxamide
CAS Number: 1143578-94-2
Molecular Formula: C₁₉H₁₇F₂N₇O
Molecular Weight: 397.381
Catalog: Signaling Pathways Metabolic Enzyme/Protease FAAH
Create Date: 2018-06-05 17:09:25
Modify Date: 2024-01-15 18:49:42
FAAH-IN-6 (compound 21d) is a potent, orally active and cross the blood-brain barrier fatty acid amide hydrolase (FAAH) inhibitor with IC50s of 0.72, 0.28 nM for hFAAH, rFAAH, respectively. FAAH-IN-6 shows dose-dependent analgesic efficacy in animal models of both neuropathic and inflammatory pain[1].

Name	4-[4-(3,4-Difluorophenyl)-2-pyrimidinyl]-N-(3-pyridazinyl)-1-piperazinecarboxamide
Synonyms	1-Piperazinecarboxamide, 4-[4-(3,4-difluorophenyl)-2-pyrimidinyl]-N-3-pyridazinyl- 4-[4-(3,4-Difluorophenyl)-2-pyrimidinyl]-N-(3-pyridazinyl)-1-piperazinecarboxamide

Description	FAAH-IN-6 (compound 21d) is a potent, orally active and cross the blood-brain barrier fatty acid amide hydrolase (FAAH) inhibitor with IC50s of 0.72, 0.28 nM for hFAAH, rFAAH, respectively. FAAH-IN-6 shows dose-dependent analgesic efficacy in animal models of both neuropathic and inflammatory pain[1].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> FAAH Research Areas >> Neurological Disease Signaling Pathways >> Neuronal Signaling >> FAAH
Target	IC50: 0.72 nM (hFAAH); 0.28 nM (rFAAH)[1]
In Vivo	FAAH-IN-6 (compound 21d) (1-10 mg/kg; p.o.) shows significantly ameliorates tactile allodynia in a dose-dependent fashion in SNI-induced neuropathic pain rats model[1]. FAAH-IN-6 (3-10 mg/kg; p.o.) shows significantly ameliorates tactile allodynia of the ipsilateral hind paw in CFA-induced inflammatory pain model[1].
References	[1]. Kono M, et al. Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors. Bioorg Med Chem. 2014 Feb 15;22(4):1468-78.